Literature DB >> 11781826

Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development.

G Li1, H Schaider, K Satyamoorthy, Y Hanakawa, K Hashimoto, M Herlyn.   

Abstract

During melanoma development, transformed cells evade keratinocyte-mediated control by downregulating cell adhesion molecules. This study investigated the regulation of cell adhesion by hepatocyte growth factor (HGF) in melanoma. Melanocytes and two melanoma lines, WM164 and WM35, expressed normal level E-cadherin and Desmoglein 1, whereas most melanomas (18 out of 20) expressed no E-cadherin and significantly reduced Desmoglein 1. Overexpression of dominant negative E-cadherin and Desmoglein in melanocytes demonstrated that both molecules contribute to adhesion between melanocytes and keratinocytes. In contrast to melanocytes, most melanomas expressed HGF. All melanocytic cells expressed the HGF receptor c-Met, and autocrine HGF caused constitutive activation of c-Met, MAPK and PI3K. When autocrine activation was induced with HGF-expressing adenovirus, E-cadherin and Desmoglein 1 were decreased in melanocytes, WM164 and WM35. MAPK inhibitor PD98059 and PI3K inhibitor wortmannin partially blocked the downregulation, suggesting that both pathways are involved in this process. c-Met was coimmunoprecipitated with E-cadherin, Desmoglein 1 and Plakoglobin, suggesting that they form a complex (es) that acts to regulate intercellular adhesion. Together, the results indicate that autocrine HGF decouples melanomas from keratinocytes by downregulating E-cadherin and Desmoglein 1, therefore frees melanoma cells from the control by keratinocytes and allows dissemination of the tumor mass.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11781826     DOI: 10.1038/sj.onc.1205034

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  57 in total

1.  Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer.

Authors:  Shuying Liu; Shunqiang Li; Bailiang Wang; Wenbin Liu; Mihai Gagea; Huiqin Chen; Joohyuk Sohn; Napa Parinyanitikul; Tina Primeau; Kim-Anh Do; George F Vande Woude; John Mendelsohn; Naoto T Ueno; Gordon B Mills; Debu Tripathy; Ana M Gonzalez-Angulo
Journal:  Mol Cancer Ther       Date:  2018-12-05       Impact factor: 6.261

Review 2.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

Review 3.  Growth factors and oncogenes as targets in melanoma: lost in translation?

Authors:  Lawrence Kwong; Lynda Chin; Stephan N Wagner
Journal:  Adv Dermatol       Date:  2007

4.  HGF-promoted motility in primary human melanocytes depends on CD44v6 regulated via NF-kappa B, Egr-1, and C/EBP-beta.

Authors:  Sabine Damm; Petra Koefinger; Martina Stefan; Christian Wels; Gabor Mehes; Erika Richtig; Helmut Kerl; Marcus Otte; Helmut Schaider
Journal:  J Invest Dermatol       Date:  2010-04-01       Impact factor: 8.551

5.  Rapid growth of invasive metastatic melanoma in carcinogen-treated hepatocyte growth factor/scatter factor-transgenic mice carrying an oncogenic CDK4 mutation.

Authors:  Damia Tormo; Aleix Ferrer; Evelyn Gaffal; Jörg Wenzel; Etiena Basner-Tschakarjan; Julia Steitz; Lukas C Heukamp; Ines Gütgemann; Reinhard Buettner; Marcos Malumbres; Mariano Barbacid; Glenn Merlino; Thomas Tüting
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

6.  Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1R.

Authors:  Kerrington R Molhoek; Amber L Shada; Mark Smolkin; Sudhir Chowbina; Jason Papin; David L Brautigan; Craig L Slingluff
Journal:  Melanoma Res       Date:  2011-08       Impact factor: 3.599

Review 7.  Tumor cell plasticity: the challenge to catch a moving target.

Authors:  Sarah Schwitalla
Journal:  J Gastroenterol       Date:  2014-02-25       Impact factor: 7.527

Review 8.  The role of altered cell-cell communication in melanoma progression.

Authors:  Nikolas K Haass; Keiran S M Smalley; Meenhard Herlyn
Journal:  J Mol Histol       Date:  2004-03       Impact factor: 2.611

Review 9.  Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?

Authors:  Michael Hölzel; Anton Bovier; Thomas Tüting
Journal:  Nat Rev Cancer       Date:  2013-03-28       Impact factor: 60.716

Review 10.  Overcoming resistance to BRAF inhibitors.

Authors:  Imanol Arozarena; Claudia Wellbrock
Journal:  Ann Transl Med       Date:  2017-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.